Proactiveinvestors Australia Synairgen PLC https://www.proactiveinvestors.com.au Proactiveinvestors Australia Synairgen PLC RSS feed en Sat, 30 May 2020 08:58:41 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Synairgen completes hospital recruitment for coronavirus trial https://www.proactiveinvestors.com.au/companies/news/920598/synairgen-completes-hospital-recruitment-for-coronavirus-trial-920598.html Thu, 28 May 2020 07:56:00 +1000 https://www.proactiveinvestors.com.au/companies/news/920598/synairgen-completes-hospital-recruitment-for-coronavirus-trial-920598.html Synairgen CEO details expansion of key coronavirus trial to patients in home https://www.proactiveinvestors.com.au/companies/news/920416/synairgen-ceo-details-expansion-of-key-coronavirus-trial-to-patients-in-home-920416.html Tue, 26 May 2020 13:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/920416/synairgen-ceo-details-expansion-of-key-coronavirus-trial-to-patients-in-home-920416.html Synairgen gets green light for home study of coronavirus inhaled drug; top line data expected in July https://www.proactiveinvestors.com.au/companies/news/920355/synairgen-gets-green-light-for-home-study-of-coronavirus-inhaled-drug-top-line-data-expected-in-july-920355.html Tue, 26 May 2020 06:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/920355/synairgen-gets-green-light-for-home-study-of-coronavirus-inhaled-drug-top-line-data-expected-in-july-920355.html Synairgen surges as it extends SNG001 study to coronavirus patients in home environment https://www.proactiveinvestors.com.au/companies/news/918523/synairgen-surges-as-it-extends-sng001-study-to-coronavirus-patients-in-home-environment-918523.html Thu, 30 Apr 2020 11:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918523/synairgen-surges-as-it-extends-sng001-study-to-coronavirus-patients-in-home-environment-918523.html Small cap movers: AIM-listed companies raise £500mln in less than a month to cope with coronavirus crisis https://www.proactiveinvestors.com.au/companies/news/918064/small-cap-movers-aim-listed-companies-raise-500mln-in-less-than-a-month-to-cope-with-coronavirus-crisis-918064.html Sat, 25 Apr 2020 09:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/918064/small-cap-movers-aim-listed-companies-raise-500mln-in-less-than-a-month-to-cope-with-coronavirus-crisis-918064.html Synairgen jumps as SNG001 trial on coronavirus patients labelled as an Urgent Public Health study https://www.proactiveinvestors.com.au/companies/news/917184/synairgen-jumps-as-sng001-trial-on-coronavirus-patients-labelled-as-an-urgent-public-health-study-917184.html Tue, 14 Apr 2020 11:38:00 +1000 https://www.proactiveinvestors.com.au/companies/news/917184/synairgen-jumps-as-sng001-trial-on-coronavirus-patients-labelled-as-an-urgent-public-health-study-917184.html Synairgen starts dosing patients in coronavirus trials https://www.proactiveinvestors.com.au/companies/news/916179/synairgen-starts-dosing-patients-in-coronavirus-trials-916179.html Tue, 31 Mar 2020 06:26:00 +1100 https://www.proactiveinvestors.com.au/companies/news/916179/synairgen-starts-dosing-patients-in-coronavirus-trials-916179.html Synairgen raises £14mln in placing to fund coronavirus trial https://www.proactiveinvestors.com.au/companies/news/915787/synairgen-raises-14mln-in-placing-to-fund-coronavirus-trial-915787.html Thu, 26 Mar 2020 09:29:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915787/synairgen-raises-14mln-in-placing-to-fund-coronavirus-trial-915787.html Synairgen to start trials for coronavirus treatment https://www.proactiveinvestors.com.au/companies/news/219796/synairgen-to-start-trials-for-coronavirus-treatment-219796.html Mon, 23 Mar 2020 12:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/219796/synairgen-to-start-trials-for-coronavirus-treatment-219796.html Synairgen to start trials this week of its lead drug in patients with COVID-19 https://www.proactiveinvestors.com.au/companies/news/915497/synairgen-to-start-trials-this-week-of-its-lead-drug-in-patients-with-covid-19-915497.html Mon, 23 Mar 2020 08:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915497/synairgen-to-start-trials-this-week-of-its-lead-drug-in-patients-with-covid-19-915497.html Why the coronavirus crisis might not be as bad as 2008; and why it might be worse https://www.proactiveinvestors.com.au/companies/news/915426/why-the-coronavirus-crisis-might-not-be-as-bad-as-2008-and-why-it-might-be-worse-915426.html Fri, 20 Mar 2020 12:48:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915426/why-the-coronavirus-crisis-might-not-be-as-bad-as-2008-and-why-it-might-be-worse-915426.html Proactive news snapshot: Synairgen, Ergomed, Westminster Group, Union Jack Oil … https://www.proactiveinvestors.com.au/companies/news/915204/proactive-news-snapshot-synairgen-ergomed-westminster-group-union-jack-oil--915204.html Wed, 18 Mar 2020 15:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915204/proactive-news-snapshot-synairgen-ergomed-westminster-group-union-jack-oil--915204.html Synairgen to start COVID-19 trial of lead drug imminently https://www.proactiveinvestors.com.au/companies/news/915182/synairgen-to-start-covid-19-trial-of-lead-drug-imminently-915182.html Wed, 18 Mar 2020 07:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915182/synairgen-to-start-covid-19-trial-of-lead-drug-imminently-915182.html Coronavirus: Small biotechs buck market trend as search for lung infection relief intensifies https://www.proactiveinvestors.com.au/companies/news/915128/coronavirus-small-biotechs-buck-market-trend-as-search-for-lung-infection-relief-intensifies-915128.html Tue, 17 Mar 2020 13:21:00 +1100 https://www.proactiveinvestors.com.au/companies/news/915128/coronavirus-small-biotechs-buck-market-trend-as-search-for-lung-infection-relief-intensifies-915128.html Proactive snapshot: Synairgen, Bushveld Minerals Limited, KR1 https://www.proactiveinvestors.com.au/companies/news/903809/proactive-snapshot-synairgen-bushveld-minerals-limited-kr1-903809.html Mon, 30 Sep 2019 15:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903809/proactive-snapshot-synairgen-bushveld-minerals-limited-kr1-903809.html Synairgen's phase II trial on lead COPD drug 'progressing well' https://www.proactiveinvestors.com.au/companies/news/903741/synairgen-s-phase-ii-trial-on-lead-copd-drug--progressing-well--903741.html Mon, 30 Sep 2019 08:45:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903741/synairgen-s-phase-ii-trial-on-lead-copd-drug--progressing-well--903741.html Synairgen set for a busy winter https://www.proactiveinvestors.com.au/companies/news/903720/synairgen-set-for-a-busy-winter-903720.html Mon, 30 Sep 2019 07:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903720/synairgen-set-for-a-busy-winter-903720.html Synairgen to share encouraging data https://www.proactiveinvestors.com.au/companies/news/903640/synairgen-to-share-encouraging-data-903640.html Fri, 27 Sep 2019 07:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903640/synairgen-to-share-encouraging-data-903640.html Synairgen phase II study making encouraging progress https://www.proactiveinvestors.com.au/companies/news/224399/synairgen-phase-ii-study-making-encouraging-progress-224399.html Wed, 24 Jul 2019 10:03:00 +1000 https://www.proactiveinvestors.com.au/companies/news/224399/synairgen-phase-ii-study-making-encouraging-progress-224399.html Synairgen to include more severe COPD patients in phase II SNG001 study https://www.proactiveinvestors.com.au/companies/news/216451/synairgen-to-include-more-severe-copd-patients-in-phase-ii-sng001-study-216451.html Thu, 14 Mar 2019 08:13:00 +1100 https://www.proactiveinvestors.com.au/companies/news/216451/synairgen-to-include-more-severe-copd-patients-in-phase-ii-sng001-study-216451.html Synairgen making headway https://www.proactiveinvestors.com.au/companies/news/215226/synairgen-making-headway-215226.html Mon, 25 Feb 2019 12:31:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215226/synairgen-making-headway-215226.html Synairgen prelims chart a year of progress https://www.proactiveinvestors.com.au/companies/news/215185/synairgen-prelims-chart-a-year-of-progress-215185.html Mon, 25 Feb 2019 07:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/215185/synairgen-prelims-chart-a-year-of-progress-215185.html Synairgen’s LOXL2 fibrosis drugs ready for phase II trials https://www.proactiveinvestors.com.au/companies/news/212781/synairgens-loxl2-fibrosis-drugs-ready-for-phase-ii-trials-212781.html Thu, 17 Jan 2019 10:53:00 +1100 https://www.proactiveinvestors.com.au/companies/news/212781/synairgens-loxl2-fibrosis-drugs-ready-for-phase-ii-trials-212781.html Synairgen kicks off part two of phase II COPD study https://www.proactiveinvestors.com.au/companies/news/207532/synairgen-kicks-off-part-two-of-phase-ii-copd-study-207532.html Mon, 22 Oct 2018 11:45:00 +1100 https://www.proactiveinvestors.com.au/companies/news/207532/synairgen-kicks-off-part-two-of-phase-ii-copd-study-207532.html Synairgen expands mid-stage COPD study as it raises £2.9mln from investors https://www.proactiveinvestors.com.au/companies/news/205662/synairgen-expands-mid-stage-copd-study-as-it-raises-29mln-from-investors-205662.html Tue, 25 Sep 2018 13:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205662/synairgen-expands-mid-stage-copd-study-as-it-raises-29mln-from-investors-205662.html Synairgen, Verona Pharma and why DCF analysis doesn't provide the full picture https://www.proactiveinvestors.com.au/companies/news/204622/synairgen-verona-pharma-and-why-dcf-analysis-doesn-t-provide-the-full-picture-204622.html Tue, 11 Sep 2018 09:11:00 +1000 https://www.proactiveinvestors.com.au/companies/news/204622/synairgen-verona-pharma-and-why-dcf-analysis-doesn-t-provide-the-full-picture-204622.html Synairgen shares jump as data shows lead COPD drug having the desired effect https://www.proactiveinvestors.com.au/companies/news/199750/synairgen-shares-jump-as-data-shows-lead-copd-drug-having-the-desired-effect-199750.html Thu, 28 Jun 2018 14:55:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199750/synairgen-shares-jump-as-data-shows-lead-copd-drug-having-the-desired-effect-199750.html Synairgen PLC pleased with further positive data from lead COPD drug https://www.proactiveinvestors.com.au/companies/news/309724/synairgen-plc-pleased-with-further-positive-data-from-lead-copd-drug-9724.html Thu, 28 Jun 2018 09:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309724/synairgen-plc-pleased-with-further-positive-data-from-lead-copd-drug-9724.html Synairgen says its drug well tolerated in phase II trial https://www.proactiveinvestors.com.au/companies/news/309664/synairgen-says-its-drug-well-tolerated-in-phase-ii-trial-9664.html Fri, 22 Jun 2018 11:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/309664/synairgen-says-its-drug-well-tolerated-in-phase-ii-trial-9664.html Synairgen’s lead drug well tolerated so far in phase II trial https://www.proactiveinvestors.com.au/companies/news/199372/synairgens-lead-drug-well-tolerated-so-far-in-phase-ii-trial-199372.html Fri, 22 Jun 2018 06:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199372/synairgens-lead-drug-well-tolerated-so-far-in-phase-ii-trial-199372.html Synairgen primed for a successful year https://www.proactiveinvestors.com.au/companies/news/193212/synairgen-primed-for-a-successful-year-193212.html Thu, 15 Mar 2018 11:24:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193212/synairgen-primed-for-a-successful-year-193212.html Synairgen says first phase II clinical trial patients have been dosed https://www.proactiveinvestors.com.au/companies/news/191273/synairgen-says-first-phase-ii-clinical-trial-patients-have-been-dosed-191273.html Wed, 07 Feb 2018 07:33:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191273/synairgen-says-first-phase-ii-clinical-trial-patients-have-been-dosed-191273.html Synairgen 's new fibrosis collaboration terms will free it to work in other areas https://www.proactiveinvestors.com.au/companies/news/188815/synairgen-s-new-fibrosis-collaboration-terms-will-free-it-to-work-in-other-areas-188815.html Thu, 14 Dec 2017 13:59:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188815/synairgen-s-new-fibrosis-collaboration-terms-will-free-it-to-work-in-other-areas-188815.html Synairgen shoots higher on new terms for fibrosis collaboration https://www.proactiveinvestors.com.au/companies/news/188777/synairgen-shoots-higher-on-new-terms-for-fibrosis-collaboration-188777.html Thu, 14 Dec 2017 12:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188777/synairgen-shoots-higher-on-new-terms-for-fibrosis-collaboration-188777.html Synairgen chief delighted with amended fibrosis collaboration deal https://www.proactiveinvestors.com.au/companies/news/308539/synairgen-chief-delighted-with-amended-fibrosis-collaboration-deal-8539.html Thu, 14 Dec 2017 11:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/308539/synairgen-chief-delighted-with-amended-fibrosis-collaboration-deal-8539.html Synairgen planning winter trial as it develops inhaled interferon beta drug for COPD https://www.proactiveinvestors.com.au/companies/news/308163/synairgen-planning-winter-trial-as-it-develops-inhaled-interferon-beta-drug-for-copd-8163.html Fri, 29 Sep 2017 07:21:00 +1000 https://www.proactiveinvestors.com.au/companies/news/308163/synairgen-planning-winter-trial-as-it-develops-inhaled-interferon-beta-drug-for-copd-8163.html SynairGen to target COPD with inhaled interferon beta treatment https://www.proactiveinvestors.com.au/companies/news/184646/synairgen-to-target-copd-with-inhaled-interferon-beta-treatment-184646.html Wed, 27 Sep 2017 06:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184646/synairgen-to-target-copd-with-inhaled-interferon-beta-treatment-184646.html Lots of potential for Synairgen in fibrosis, suggests broker finncap https://www.proactiveinvestors.com.au/companies/news/183540/lots-of-potential-for-synairgen-in-fibrosis-suggests-broker-finncap-183540.html Wed, 06 Sep 2017 11:52:00 +1000 https://www.proactiveinvestors.com.au/companies/news/183540/lots-of-potential-for-synairgen-in-fibrosis-suggests-broker-finncap-183540.html Synairgen reports strong interest in new fibrosis treatment ahead of Phase I trial https://www.proactiveinvestors.com.au/companies/news/183511/synairgen-reports-strong-interest-in-new-fibrosis-treatment-ahead-of-phase-i-trial-183511.html Wed, 06 Sep 2017 06:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/183511/synairgen-reports-strong-interest-in-new-fibrosis-treatment-ahead-of-phase-i-trial-183511.html Synairgen pleased with the progress made with the LOXL2 programme https://www.proactiveinvestors.com.au/companies/news/177900/synairgen-pleased-with-the-progress-made-with-the-loxl2-programme-177900.html Wed, 17 May 2017 08:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/177900/synairgen-pleased-with-the-progress-made-with-the-loxl2-programme-177900.html Synairgen believes interferon beta candidate has potential https://www.proactiveinvestors.com.au/companies/news/176987/synairgen-believes-interferon-beta-candidate-has-potential-176987.html Thu, 27 Apr 2017 07:44:00 +1000 https://www.proactiveinvestors.com.au/companies/news/176987/synairgen-believes-interferon-beta-candidate-has-potential-176987.html Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme https://www.proactiveinvestors.com.au/companies/news/307083/synairgen-s-chief-hails-exciting-ipf-data-from-loxl2-inhibitor-programme-7083.html Fri, 10 Mar 2017 15:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/307083/synairgen-s-chief-hails-exciting-ipf-data-from-loxl2-inhibitor-programme-7083.html Synairgen eyes lung fibrosis trial after encouraging lab results https://www.proactiveinvestors.com.au/companies/news/174607/synairgen-eyes-lung-fibrosis-trial-after-encouraging-lab-results-174607.html Fri, 10 Mar 2017 15:10:00 +1100 https://www.proactiveinvestors.com.au/companies/news/174607/synairgen-eyes-lung-fibrosis-trial-after-encouraging-lab-results-174607.html Brokers: Synairgen still a buy after Astra decision, finnCap says https://www.proactiveinvestors.com.au/companies/news/276255/brokers-synairgen-still-a-buy-after-astra-decision-finncap-says-26255.html Wed, 12 Oct 2016 10:32:00 +1100 https://www.proactiveinvestors.com.au/companies/news/276255/brokers-synairgen-still-a-buy-after-astra-decision-finncap-says-26255.html “Not the end of the road” for Synairgen’s asthma treatment https://www.proactiveinvestors.com.au/companies/news/306170/not-the-end-of-the-road-for-synairgens-asthma-treatment-6170.html Wed, 12 Oct 2016 10:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/306170/not-the-end-of-the-road-for-synairgens-asthma-treatment-6170.html AstraZeneca likely to adapt clinical trial of Synairgen drug https://www.proactiveinvestors.com.au/companies/news/167273/astrazeneca-likely-to-adapt-clinical-trial-of-synairgen-drug-167273.html Wed, 12 Oct 2016 10:09:00 +1100 https://www.proactiveinvestors.com.au/companies/news/167273/astrazeneca-likely-to-adapt-clinical-trial-of-synairgen-drug-167273.html Synairgen on schedule with all of its drug programmes https://www.proactiveinvestors.com.au/companies/news/166315/synairgen-on-schedule-with-all-of-its-drug-programmes-166315.html Thu, 22 Sep 2016 10:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/166315/synairgen-on-schedule-with-all-of-its-drug-programmes-166315.html High profile financier Leonard Licht invests in Synairgen https://www.proactiveinvestors.com.au/companies/news/125095/high-profile-financier-leonard-licht-invests-in-synairgen Thu, 21 Apr 2016 14:28:00 +1000 https://www.proactiveinvestors.com.au/companies/news/125095/high-profile-financier-leonard-licht-invests-in-synairgen Synairgen PLC and why the market is not the best arbiter of value https://www.proactiveinvestors.com.au/companies/news/124437/synairgen-plc-and-why-the-market-is-not-the-best-arbiter-of-value-124437.html Tue, 05 Apr 2016 10:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/124437/synairgen-plc-and-why-the-market-is-not-the-best-arbiter-of-value-124437.html Synairgen plc looking for more collaborations, says chief https://www.proactiveinvestors.com.au/companies/news/304846/synairgen-plc-looking-for-more-collaborations-says-chief-4846.html Mon, 04 Apr 2016 08:17:00 +1000 https://www.proactiveinvestors.com.au/companies/news/304846/synairgen-plc-looking-for-more-collaborations-says-chief-4846.html Synairgen makes progress with lung drug https://www.proactiveinvestors.com.au/companies/news/123960/synairgen-makes-progress-with-lung-drug-123960.html Tue, 22 Mar 2016 10:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/123960/synairgen-makes-progress-with-lung-drug-123960.html Synairgen PLC's potential is Astra-nomical https://www.proactiveinvestors.com.au/companies/news/62898/synairgen-plcs-potential-is-astra-nomical-73485.html Tue, 21 Oct 2014 14:05:00 +1100 https://www.proactiveinvestors.com.au/companies/news/62898/synairgen-plcs-potential-is-astra-nomical-73485.html Synairgen - Investor Presentation - October 9th 2014 https://www.proactiveinvestors.com.au/companies/news/302758/synairgen-investor-presentation-october-9th-2014-3153.html Fri, 10 Oct 2014 07:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/302758/synairgen-investor-presentation-october-9th-2014-3153.html Synairgen, Advanced Computer Software, Sphere Medical at next forum https://www.proactiveinvestors.com.au/companies/news/62393/synairgen-advanced-computer-software-sphere-medical-at-next-forum-72917.html Next Thursday 9th October we are joined by the executive directors of AIM-quoted Synairgen (LON:SNG), Sphere Medical (AIM:SPHR) and Advanced Computer Software (LON:ASW) in what promises to be a fascinating evening. To register please clickhere

]]>
Fri, 03 Oct 2014 16:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/62393/synairgen-advanced-computer-software-sphere-medical-at-next-forum-72917.html
UPDATE- Synairgen interims chart transformational six months https://www.proactiveinvestors.com.au/companies/news/62087/update-synairgen-interims-chart-transformational-six-months--72599.html Thu, 25 Sep 2014 09:36:00 +1000 https://www.proactiveinvestors.com.au/companies/news/62087/update-synairgen-interims-chart-transformational-six-months--72599.html Synairgen replenishes the coffers; broker points to value proposition https://www.proactiveinvestors.com.au/companies/news/59722/synairgen-replenishes-the-coffers-broker-points-to-value-proposition-70097.html Fri, 04 Jul 2014 09:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/59722/synairgen-replenishes-the-coffers-broker-points-to-value-proposition-70097.html Synairgen chief thrilled with AstraZeneca deal https://www.proactiveinvestors.com.au/companies/news/302499/synairgen-chief-thrilled-with-astrazeneca-deal--2850.html Thu, 12 Jun 2014 14:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/302499/synairgen-chief-thrilled-with-astrazeneca-deal--2850.html Synairgen chief says AstraZeneca is perfect partner as co seals quarter of a billion dollar deal https://www.proactiveinvestors.com.au/companies/news/59053/synairgen-chief-says-astrazeneca-is-perfect-partner-as-co-seals-quarter-of-a-billion-dollar-deal-69394.html Synairgen chief executive Richard Marsden described AstraZeneca as the perfect partner to take to take his firm’s potentially breakthrough asthma treatment over the regulatory hurdles and, hopefully, onto the market.

]]>
Thu, 12 Jun 2014 13:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/59053/synairgen-chief-says-astrazeneca-is-perfect-partner-as-co-seals-quarter-of-a-billion-dollar-deal-69394.html
Synairgen shares soar on AstraZeneca asthma deal https://www.proactiveinvestors.com.au/companies/news/59044/synairgen-shares-soar-on-astrazeneca-asthma-deal-69385.html Thu, 12 Jun 2014 08:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/59044/synairgen-shares-soar-on-astrazeneca-asthma-deal-69385.html Synairgen raises £2.5 million to advance respiratory drug https://www.proactiveinvestors.com.au/companies/news/38204/synairgen-raises-25-million-to-advance-respiratory-drug--45675.html Wed, 18 Jul 2012 07:50:00 +1000 https://www.proactiveinvestors.com.au/companies/news/38204/synairgen-raises-25-million-to-advance-respiratory-drug--45675.html Synairgen shares up on positive results for IFN-beta in viral pneumonia study https://www.proactiveinvestors.com.au/companies/news/30235/-synairgen-shares-up-on-positive-results-for-ifn-beta-in-viral-pneumonia-study-36139.html Fri, 25 Nov 2011 12:27:00 +1100 https://www.proactiveinvestors.com.au/companies/news/30235/-synairgen-shares-up-on-positive-results-for-ifn-beta-in-viral-pneumonia-study-36139.html Synairgen shares rocket on news of positive experiment data for inhaled interferon beta https://www.proactiveinvestors.com.au/companies/news/1214/-synairgen-shares-rocket-on-news-of-positive-experiment-data-for-inhaled-interferon-beta-9987.html Mon, 09 Nov 2009 09:26:00 +1100 https://www.proactiveinvestors.com.au/companies/news/1214/-synairgen-shares-rocket-on-news-of-positive-experiment-data-for-inhaled-interferon-beta-9987.html Synairgen gears up for next stage of IFN-beta programme https://www.proactiveinvestors.com.au/companies/news/5903/synairgen-gears-up-for-next-stage-of-ifn-beta-programme-7835.html Fri, 04 Sep 2009 13:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/5903/synairgen-gears-up-for-next-stage-of-ifn-beta-programme-7835.html Synairgen reports encouraging data from inhaled interferon beta trial https://www.proactiveinvestors.com.au/companies/news/3581/synairgen-reports-encouraging-data-from-inhaled-interferon-beta-trial-5048.html Wed, 01 Apr 2009 10:43:00 +1100 https://www.proactiveinvestors.com.au/companies/news/3581/synairgen-reports-encouraging-data-from-inhaled-interferon-beta-trial-5048.html